Voltar
Artigo Revisado por pares
BIBTEX RIS

Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study

2024; Elsevier BV; Volume: 19; Issue: 6 Linguagem: Inglês

10.1016/j.jtho.2024.01.012

ISSN

1556-1380

Autores

Amin H. Nassar, So Yeon Kim, Jacqueline V. Aredo, Jamie Feng, Frances A. Shepherd, Chao Xu, David Kaldas, Jhanelle E. Gray, Thomas J. Dilling, Joel W. Neal, Heather A. Wakelee, Yufei Liu, Steven H. Lin, Tariq Abuali, Arya Amini, Yunan Nie, Tejas Patil, Anastasiya Lobachov, Jair Bar, Bailey G. Fitzgerald, Yu Fujiwara, Thomas U. Marron, Rohit Thummalapalli, Helena A. Yu, Dwight H. Owen, John Sharp, Saira Farid, Pedro Rocha, Edurne Arriola, Angelica D’Aiello, Haiying Cheng, Ryan M. Whitaker, Kaushal Parikh, Yash P. Ashara, Luxi Chen, K. Nathan Sankar, Jeremy P. Harris, Misako Nagasaka, Adanma Ayanambakkam, Ana I. Velázquez, Meera Ragavan, W. Marston Linehan, Zofia Piotrowska, M. Wilgucki, Joshua E. Reuss, H Lüders, Christian Grohé, Javier Baena Espinar, Ella Feiner, Salman R. Punekar, Shruti Gupta, Ticiana Leal, David J. Kwiatkowski, Raymond H. Mak, Elio Adib, Abdul Rafeh Naqash, Sarah B. Goldberg,

Tópico(s)

Pancreatic and Hepatic Oncology Research

Referência(s)